Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
Abstract
BACKGROUND: ODYSSEY trial showed superior efficacy of dolutegravir-based antiretroviral therapy (ART) versus then-current, non-dolutegravir standard of care over 96 weeks in children and adolescents living with HIV. The aim of this ancillary analysis was to compare anthropometric and body composition outcomes, including weight, height, BMI-for-age Z score, weight-for-age and height-for-age Z scores (
Fields of Study & Subjects
HIV-related health complications and treatments
HIV/AIDS drug development and treatment
HIV/AIDS Research and Interventions
Publication details
- Journal / source
- The Lancet Child & Adolescent Health
- Publisher
- Elsevier BV
- Volume
- 10
- Issue
- 3
- Pages
- 189–202
- Publication date
- 21 January 2026
- Language
- EN